Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
- Russell Harris, MD, MPH; and
- Kathleen N. Lohr, PhD
-
From University of North Carolina at Chapel Hill, Chapel Hill, and Research Triangle Institute, Research Triangle Park, North
Carolina.
-
Figure. The number of cancer cases detected would be smaller after repeated annual screening. * For men in their 50s, = 50;
for men in their 70s, = 270. † For men in their 50s, = 150; for men in their 70s, = 400. ‡ For men in their 50s, = 17; for
men in their 70s, = 90. § For men in their 50s, = 30; for men in their 70s, = 100. ‖For men in their 50s, = 12; for men in
their 70s, = 63. ¶ For men in their 50s, = 21; for men in their 70s, = 70. In all footnotes, numbers are approximate. Estimated yield of screening with prostate-specific antigen (PSA) testing or with PSA testing and digital rectal examination
(DRE).nnnnnnnnnnnn
-
Appendix (Figure 1). Arrows represent steps in the chain of logic connecting screening with reduced morbidity or mortality
from prostate cancer. KQ = key question. Analytic framework for screening for prostate cancer.
-
Appendix (Figure 2). Direct evidence of screening efficacy. Ecologic studies of screening efficacy. RCT = randomized, controlled
trial. Selection of articles based on key question 1.Top.Bottom.
-
Appendix (Figure 3). Arrows represent steps in the chain of logic connecting screening with reduced morbidity or mortality
from prostate cancer. Selection of articles based on key question 2.
-
Appendix (Figure 4). Key questions 3 through 6 address health outcomes of treatment; key question 7 addresses harms of treatment.
RCT = randomized, controlled trial. Selection of articles based on key questions 3 through 6 (top) and top question 7 (bottom).
-
Appendix 5. Key question 8 addresses costs and cost-effectiveness of screening, and key question 9 deals with the harms of
screening. Selection of articles based on key questions 8 (top) and 9 (bottom).
- Copyright ©2004 by the American College of Physicians
-
Ann Intern Med
December 3, 2002
vol. 137
no. 11
917-929
RSS Feeds
View larger version:Figure. The number of cancer cases detected would be smaller after repeated annual screening. * For men in their 50s, = 50; for men in their 70s, = 270. † For men in their 50s, = 150; for men in their 70s, = 400. ‡ For men in their 50s, = 17; for men in their 70s, = 90. § For men in their 50s, = 30; for men in their 70s, = 100. ‖For men in their 50s, = 12; for men in their 70s, = 63. ¶ For men in their 50s, = 21; for men in their 70s, = 70. In all footnotes, numbers are approximate. Estimated yield of screening with prostate-specific antigen (PSA) testing or with PSA testing and digital rectal examination (DRE).nnnnnnnnnnnn
View larger version:Appendix (Figure 1). Arrows represent steps in the chain of logic connecting screening with reduced morbidity or mortality from prostate cancer. KQ = key question. Analytic framework for screening for prostate cancer.
View larger version:Appendix (Figure 2). Direct evidence of screening efficacy. Ecologic studies of screening efficacy. RCT = randomized, controlled trial. Selection of articles based on key question 1.Top.Bottom.
View larger version:Appendix (Figure 3). Arrows represent steps in the chain of logic connecting screening with reduced morbidity or mortality from prostate cancer. Selection of articles based on key question 2.
View larger version:Appendix (Figure 4). Key questions 3 through 6 address health outcomes of treatment; key question 7 addresses harms of treatment. RCT = randomized, controlled trial. Selection of articles based on key questions 3 through 6 (top) and top question 7 (bottom).
View larger version:Appendix 5. Key question 8 addresses costs and cost-effectiveness of screening, and key question 9 deals with the harms of screening. Selection of articles based on key questions 8 (top) and 9 (bottom).
Related Clinical Content
